Labiana Health (XMAD:LAB) Other Long-Term Liabilities: €0.03 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:LAB Labiana Health SA XMAD:LAB
57 GF Score
Price €6.60
GF Value €3.59
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Labiana Health Other Long-Term Liabilities?

Labiana Health XMAD:LAB -0.75% 57 Other Long-Term Liabilities is €0.03 Mil as of Dec. 2025. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.59 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Labiana Health's other long-term liabilities for the quarter that ended in Dec. 2025 was €0.03 Mil.

Labiana Health's quarterly other long-term liabilities declined from Dec. 2024 (€0.03 Mil) to Jun. 2025 (€0.03 Mil) and declined from Jun. 2025 (€0.03 Mil) to Dec. 2025 (€0.03 Mil).

Labiana Health's annual other long-term liabilities declined from Dec. 2023 (€0.36 Mil) to Dec. 2024 (€0.03 Mil) and declined from Dec. 2024 (€0.03 Mil) to Dec. 2025 (€0.03 Mil).

Labiana Health Other Long-Term Liabilities Related Terms

Labiana Health Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Labiana Health's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labiana Health Other Long-Term Liabilities Chart

Labiana Health Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial 0.99 0.54 0.36 0.03 0.03

Labiana Health Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.03 0.03 0.03 0.03
XMAD:LAB
57GF Score
Labiana Health SA XMAD:LAB
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Labiana Health Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €0.03 Mil mean?
Labiana Health (XMAD:LAB) has a Other Long-Term Liabilities of €0.03 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Labiana Health and its competitors.
Is Labiana Health's Other Long-Term Liabilities too high?
Labiana Health's current Other Long-Term Liabilities is €0.03 Mil. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Other Long-Term Liabilities compare to ZTS and UTHR?
Labiana Health's Other Long-Term Liabilities of €0.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Labiana Health and its competitors. Labiana Health's current Other Long-Term Liabilities is €0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.60 — trading 83.8% above its estimated fair value. The current Other Long-Term Liabilities is €0.03 Mil. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Other Long-Term Liabilities is €0.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Labiana Health (XMAD:LAB) Overvalued in 2026?

Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued. The current stock price of €6.60 is trading 83.8% above its estimated GF Value™ of €3.59. GuruFocus considers Labiana Health to be Significantly Overvalued.

Key valuation signals for XMAD:LAB:

  • Other Long-Term Liabilities: €0.03 Mil
  • GF Value™: €3.59 vs. price of €6.60 (83.8% above fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Labiana Health Business Description

Other Exchanges 8RK:Germany
Address Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score

Get the complete analysis for XMAD:LAB

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price
€3.59
GF Value